If a patient vomits within 3 hours of taking levonorgestrel, it is recommended to prescribe a second dose of emergency hormonal contraception to be taken as soon as possible, according to NICE guidelines. Therefore, reassuring Zoe that she is protected from pregnancy is incorrect. It is also not advisable to immediately start Zoe on the COCP, as the most important advice is to take a second dose of emergency contraception. Additionally, Zoe should be offered a range of contraceptive options, including long-acting reversible contraceptives. Suggesting other forms of emergency contraception, such as ulipristal acetate or the IUD, is also incorrect in this situation, as the guidelines specify that a second dose of levonorgestrel should be taken. However, if Zoe experiences persistent vomiting or diarrhea for more than 24 hours after taking emergency hormonal contraception, the IUD may be considered.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

Antenatal care is an important aspect of pregnancy, and the National Institute for Health and Care Excellence (NICE) has issued guidelines on routine care for healthy pregnant women. The guidelines recommend 10 antenatal visits for first pregnancies and 7 visits for subsequent pregnancies, provided that the pregnancy is uncomplicated. Women do not need to see a consultant if their pregnancy is uncomplicated.

The timetable for antenatal visits begins with a booking visit between 8-12 weeks, where general information is provided on topics such as diet, alcohol, smoking, folic acid, vitamin D, and antenatal classes. Blood and urine tests are also conducted to check for conditions such as hepatitis B, syphilis, and asymptomatic bacteriuria. An early scan is conducted between 10-13+6 weeks to confirm dates and exclude multiple pregnancies, while Down’s syndrome screening is conducted between 11-13+6 weeks.

At 16 weeks, women receive information on the anomaly and blood results, and if their haemoglobin levels are below 11 g/dl, they may be advised to take iron supplements. Routine care is conducted at 18-20+6 weeks, including an anomaly scan, and at 25, 28, 31, and 34 weeks, where blood pressure, urine dipstick, and symphysis-fundal height (SFH) are checked. Women who are rhesus negative receive anti-D prophylaxis at 28 and 34 weeks.

At 36 weeks, presentation is checked, and external cephalic version may be offered if indicated. Information on breastfeeding, vitamin K, and ‘baby-blues’ is also provided. Routine care is conducted at 38 weeks, and at 40 weeks (for first pregnancies), discussion about options for prolonged pregnancy takes place. At 41 weeks, labour plans and the possibility of induction are discussed. The RCOG advises that either a single-dose or double-dose regime of anti-D prophylaxis can be used, depending on local factors.

All pregnant women are now advised to take 10mcg of vitamin D throughout their pregnancy. Additionally, low dose folic acid is recommended for the first 12 weeks of pregnancy for all women. However, those with pregnancies at a higher risk of neural tube defects should take 5mg of folic acid during the first 12 weeks. This includes couples where either partner has a neural tube defect or a family history of such defects, those who have had a previous pregnancy affected by a neural tube defect, or women with coeliac disease, diabetes mellitus, sickle-cell anaemia, or who are taking antiepileptic medication.

Vitamin D supplementation has been a topic of interest for several years, and recent releases have provided some clarity on the matter. The Chief Medical Officer’s 2012 letter and the National Osteoporosis Society’s 2013 UK Vitamin D guideline recommend that certain groups take vitamin D supplements. These groups include pregnant and breastfeeding women, children aged 6 months to 5 years, adults over 65 years, and individuals who are not exposed to much sun, such as housebound patients.

Testing for vitamin D deficiency is not necessary for most people. The NOS guidelines suggest that testing may be appropriate for patients with bone diseases that may be improved with vitamin D treatment, such as osteomalacia or Paget’s disease, and for patients with musculoskeletal symptoms that could be attributed to vitamin D deficiency, such as bone pain. However, patients with osteoporosis should always be given calcium/vitamin D supplements, and individuals at higher risk of vitamin D deficiency should be treated regardless of testing. Overall, vitamin D supplementation is recommended for certain groups, while testing for deficiency is only necessary in specific situations.

Treatment Options for Urinary Incontinence

Bladder training is a highly effective treatment for urge or mixed incontinence. It has fewer adverse effects and lower relapse rates compared to antimuscarinic drugs, which are the next line of treatment. On the other hand, pelvic floor muscle training is recommended as the first line of treatment for stress incontinence symptoms.

Duloxetine is only recommended for stress incontinence and may be offered as a second-line treatment for women who prefer pharmacological treatment over surgery. However, modification of fluid intake is not routinely recommended. It is only recommended if fluid intake is high or low and in cases of urinary incontinence or overactive bladder.

In summary, there are various treatment options available for urinary incontinence, depending on the type and severity of the symptoms. It is important to consult with a healthcare professional to determine the most appropriate treatment plan.

The patient should be informed that their future fertility is not impacted by the abortion and there is no association with placenta praevia, ectopic pregnancy, stillborn or miscarriage. However, they should also be made aware of the potential complications that may arise from the procedure. These include severe bleeding, uterine perforation (surgical abortion only), and cervical trauma (surgical abortion only). The risks of these complications are lower for early abortions and those performed by experienced clinicians. In the event that one of these complications occurs, further treatment such as blood transfusion, laparoscopy or laparotomy may be required. Additionally, infection may occur after medical or surgical abortion, but this risk can be reduced through prophylactic antibiotic use and bacterial screening for lower genital tract infection.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, although in emergencies, only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise. The method used to terminate pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone followed by prostaglandins is used, while surgical dilation and suction of uterine contents are used for pregnancies less than 13 weeks. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion is used. The 1967 Abortion Act outlines the conditions under which a person shall not be guilty of an offense under the law relating to abortion. These limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

Pathogens and Pregnancy: What You Need to Know

Although various pathogens can colonize and infect the vagina during pregnancy, only syphilis is routinely tested for. Adequate treatment of syphilis before 18 weeks of pregnancy can prevent infection of the fetus, while treatment after 18 weeks can cure an infected fetus. Failure to treat syphilis can result in congenital syphilis, which can have long-term consequences.

herpesvirus is not routinely screened for during pregnancy, but if a woman contracts genital herpes for the first time during the first trimester, there is a small risk of miscarriage. If first infection occurs later in the pregnancy, a caesarean section may be offered to prevent the baby from coming into contact with active sores. The risk of passing on a newly caught infection to the baby during vaginal birth is about 4 in 10, but neonatal herpes is very rare in the UK, affecting only 1-2 in every 100,000 babies born.

Strep B is not routinely tested for during pregnancy, but about one in five pregnant women in the UK carry group B Streptococci bacteria. While most pregnant women who carry these bacteria have healthy babies, there is a small risk that infection can pass to the baby during childbirth. Group B Strep infection in newborn babies can cause serious complications that can be life-threatening, and even with the best medical care, one in 10 babies diagnosed with early-onset infection will die.

HPV and gonorrhea are not routinely tested for during pregnancy. It is important for pregnant women to discuss any concerns about sexually transmitted infections with their healthcare provider to ensure the best possible outcomes for themselves and their babies.

Although the progestogen-only pill can be used in combination with HRT, it cannot serve as the sole progestogen component. Women aged 40 and above can use the combined oral contraceptive pill, which is classified as UKMEC2. For women over 45 years, Depo-Provera is also classified as UKMEC2.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

Typically, cervical screening is postponed until 3 months after giving birth, unless there was a missed screening or previous abnormal results. Smear tests are not conducted while pregnant, and there is no reason to refer for colposcopy based on the patient’s history. It is standard practice to delay smear tests until 3 months after delivery.

Understanding Cervical Cancer Screening in the UK

Cervical cancer screening is a well-established program in the UK that aims to detect Premalignant changes in the cervix. This program is estimated to prevent 1,000-4,000 deaths per year. However, it should be noted that cervical adenocarcinomas, which account for around 15% of cases, are frequently undetected by screening.

The screening program has evolved significantly in recent years. Initially, smears were examined for signs of dyskaryosis, which may indicate cervical intraepithelial neoplasia. However, the introduction of HPV testing allowed for further risk stratification. Patients with mild dyskaryosis who were HPV negative could be treated as having normal results. The NHS has now moved to an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

All women between the ages of 25-64 years are offered a smear test. Women aged 25-49 years are screened every three years, while those aged 50-64 years are screened every five years. Cervical screening cannot be offered to women over 64, unlike breast screening, where patients can self-refer once past screening age. In Scotland, screening is offered from 25-64 every five years.

In special situations, cervical screening in pregnancy is usually delayed until three months postpartum, unless there has been missed screening or previous abnormal smears. Women who have never been sexually active have a very low risk of developing cervical cancer and may wish to opt-out of screening.

While there is limited evidence to support it, the current advice given out by the NHS is that the best time to take a cervical smear is around mid-cycle. Understanding the cervical cancer screening program in the UK is crucial for women to take control of their health and prevent cervical cancer.

Lactational Amenorrhoea Method (LAM) as a Contraceptive

Breastfeeding can be used as a form of contraception through the lactational amenorrhoea method (LAM). This method works by suppressing ovarian activity, which prevents the return of menstrual periods after childbirth. For LAM to be effective, a woman must engage in full breastfeeding, which includes exclusive or almost exclusive breastfeeding with no other liquids or solids given.

If the frequency or duration of breastfeeding decreases, the risk of menstrual periods and fertility increases. Women who experience bleeding within the first six months after childbirth have a higher risk of pregnancy than those who remain amenorrhoeic. To use LAM as a contraceptive, a woman must meet all three criteria: fully or nearly fully breastfeeding day and night, no long intervals between feeds, and amenorrhoeic and less than six months postpartum.

When the rules of LAM are strictly followed, failure rates are less than 2%. Therefore, LAM can be an effective and natural form of contraception for women who choose to breastfeed their infants.

Starting Contraception: Important Considerations

When starting contraception, it is important for the clinician to ensure that the woman is likely to continue to be at risk of pregnancy or has expressed a preference to begin contraception immediately. Additionally, the woman should be aware that she may be pregnant and that there are theoretical risks from contraceptive exposure to the fetus, although evidence indicates no harm. It is also important to note that pregnancy can only be excluded once a pregnancy test is negative at least three weeks after the last episode of unprotected sexual intercourse. Therefore, the woman should be advised to carry out a pregnancy test at least three weeks after the last episode of unprotected sexual intercourse and advised on additional contraception. While a negative pregnancy test is not required before starting contraception, the clinician should be reasonably sure that the woman is not pregnant or at risk of pregnancy. It is important to keep in mind that this practice may be outside the product licence.

Causes of Vaginal Discharge in Women

This woman is experiencing occasional vaginal discharge. There are several potential causes of vaginal discharge, including candidiasis, bacterial vaginosis, and physiological discharge. Candidiasis is typically associated with itch and a thick discharge, while bacterial vaginosis is often intermittent and accompanied by a profuse and smelly discharge. However, given the patient’s age and stable relationship, physiological discharge is the most likely cause.

In this case, it may not be necessary to conduct a speculum exam unless the patient specifically requests it. Initially, the patient can be reassured without further investigation. However, if investigation is deemed necessary, a self-taken lower vaginal swab would be a reasonable option.

It is important to note that normality is a common theme in the MRCGP exam, and understanding the various causes of vaginal discharge is an important aspect of primary care.

Women who have taken ulipristal acetate should wait for at least 5 days before starting regular hormonal contraception, according to current guidelines. This is because ulipristal acetate may decrease the effectiveness of hormonal contraception. Additionally, taking desogestrel hormonal contraception within 5 days of ulipristal acetate can also reduce the efficacy of emergency contraception. It is recommended to use additional precautions until contraceptive cover is re-established, and if desogestrel is being used, this should be after 48 hours. It would be helpful to discuss long-acting reversible contraception options with the patient in this case.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

Prenatal Screening Tests: An Overview

One of the routine tests offered to pregnant women is the second trimester anomaly scan, which screens for fetal abnormalities. However, for more specific testing, amniocentesis and chorionic villus sampling (CVS) are available. Amniocentesis is typically done between weeks 15-20 of pregnancy and can detect Down’s syndrome, spina bifida, and other conditions. CVS, on the other hand, is done between weeks 10-13 and is only offered to those with a high risk of serious inherited conditions. The first trimester scan is mainly used to confirm and date the pregnancy, while the second trimester anomaly scan is used to detect fetal abnormalities. The nuchal translucency (NT) scan is also offered as part of the NHS screening program between weeks 11-13.6 of pregnancy. It’s important to note that while these tests are available, they are not routinely offered to all women and carry a small risk of miscarriage.

Bacterial vaginosis during pregnancy can lead to various pregnancy-related issues, such as preterm labor. In the past, it was advised to avoid taking oral metronidazole during the first trimester. However, current guidelines suggest that it is safe to use throughout the entire pregnancy. For more information, please refer to the Clinical Knowledge Summary provided.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimens. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

Most pathologists hold the view that uterine leiomyosarcomas, which may appear as ‘fibroids’ at first, are most likely new growths rather than a conversion of pre-existing fibroids.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are believed to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility, but this is rare.

Diagnosis is usually done through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is necessary. For menorrhagia, treatment options include the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, oral progestogen, and injectable progestogen. Medical treatment to shrink or remove fibroids includes GnRH agonists and ulipristal acetate, while surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, and complications such as subfertility and iron-deficiency anaemia have been mentioned previously. Another complication is red degeneration, which is haemorrhage into the tumour and commonly occurs during pregnancy. Understanding uterine fibroids is important for women’s health, and seeking medical attention is necessary if symptoms arise.

According to the guidelines of the Faculty of Sexual and Reproductive Health and the BNF, the recommended contraceptive method in this case is injectable progesterone. This method is not affected by drug interactions. However, as topiramate is an enzyme inducer, it can reduce the effectiveness of oestrogens and progesterone, which are components of combined contraceptive pills. Therefore, if a combined contraceptive pill is to be used, it should contain at least 50 micrograms of ethinyl estradiol. Barrier methods alone are not reliable and should not be used as the sole form of contraception. Progesterone-only pills and implants are not suitable due to the enhanced first pass metabolism of progesterone, which can result in decreased contraceptive efficacy.

Contraception for Women with Epilepsy

Women with epilepsy need to consider several factors when choosing a contraceptive method. The effectiveness of anti-epileptic medication can be affected by the contraceptive, and vice versa. Additionally, if a woman becomes pregnant while taking anti-epileptic medication, there is a risk of teratogenic effects on the fetus. To address these concerns, the Faculty of Sexual & Reproductive Healthcare (FSRH) recommends the consistent use of condoms in addition to other forms of contraception.

For women taking certain anti-epileptic medications such as phenytoin, carbamazepine, barbiturates, primidone, topiramate, and oxcarbazepine, the FSRH recommends using the combined oral contraceptive pill (COCP) or progestogen-only pill (POP) with a UK Medical Eligibility Criteria (UKMEC) rating of 3. The implant has a UKMEC rating of 2, while the Depo-Provera injection, intrauterine device (IUD), and intrauterine system (IUS) have a UKMEC rating of 1.

For women taking lamotrigine, the FSRH recommends using the COCP with a UKMEC rating of 3 or the POP, implant, Depo-Provera injection, IUD, or IUS with a UKMEC rating of 1. If a COCP is chosen, it should contain a minimum of 30 µg of ethinylestradiol.

In summary, women with epilepsy should carefully consider the potential interactions between their anti-epileptic medication and their chosen contraceptive method. Using condoms consistently in addition to other forms of contraception can help reduce the risk of unintended pregnancy and potential teratogenic effects on the fetus.

Premature Ovarian Insufficiency: Causes, Symptoms, and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flashes, night sweats, infertility, secondary amenorrhoea, and elevated FSH and LH levels. Hormone replacement therapy or a combined oral contraceptive pill is recommended until the age of the average menopause, which is 51 years. It is important to note that HRT doesn’t provide contraception in case spontaneous ovarian activity resumes.

Criteria for Exclusion of Pregnancy

Health professionals can confidently exclude pregnancy in women if certain criteria are met. These include not having had intercourse since the last normal menstrual period, consistent use of reliable contraception, being within the first seven days of a normal menstrual period, being within four weeks postpartum for non-lactating women, being within the first seven days post-abortion or miscarriage, or being fully or nearly fully breastfeeding, amenorrhoeic, and less than six months postpartum.

While a pregnancy test can provide additional confirmation, it should only be carried out at least three weeks after the last episode of unprotected sexual intercourse. If a woman is at risk of pregnancy due to recent unprotected intercourse, a pregnancy test should be considered within the first seven days. By following these guidelines, health professionals can accurately exclude pregnancy and provide appropriate care for their patients.

During pregnancy, fibroid degeneration can occur and may cause symptoms such as low-grade fever, pain, and vomiting. If an ultrasound scan shows no signs of inflammation in the appendix, it is unlikely that the patient has appendicitis. Given the presence of fibroids in the uterus, the patient is at risk of experiencing fibroid degeneration, particularly red degeneration, which can cause fever, pain, and vomiting. The absence of vaginal bleeding makes it unlikely that the patient is experiencing a threatened miscarriage. Ovarian torsion typically presents with pain and vomiting, but it is usually associated with risk factors such as ovarian cysts or enlargement.

Understanding Fibroid Degeneration

Uterine fibroids are non-cancerous growths that can develop in the uterus. They are known to be sensitive to oestrogen and can grow during pregnancy. However, if the growth of the fibroids exceeds their blood supply, they can undergo a type of degeneration known as red or ‘carneous’ degeneration. This condition is characterized by symptoms such as low-grade fever, pain, and vomiting.

Fortunately, fibroid degeneration can be managed conservatively with rest and analgesia. With proper care, the symptoms should resolve within 4-7 days. It is important to note that fibroid degeneration is a common occurrence and doesn’t necessarily indicate a serious underlying condition.

Importance of Waiting for Cervical Epithelium Regeneration and Antimicrobial Treatment

It is crucial to wait for at least three months for the regeneration of the cervical epithelium after a screening test. This is because the epithelium needs time to heal and regenerate before another test is conducted. Rushing to re-sample before the regeneration of the epithelium can lead to inaccurate results, which can be detrimental to the patient’s health.

Moreover, if there is any suspicion of infection, antimicrobial treatment should be administered before re-sampling. This is because an infection can interfere with the accuracy of the test results, leading to false positives or false negatives. Therefore, it is essential to wait for the regeneration of the cervical epithelium and treat any suspected infection before conducting another screening test.

The use of the combined oral contraceptive pill could potentially alleviate certain symptoms experienced during perimenopause and help preserve bone mineral density.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

After giving birth, women need to use contraception after 21 days. The Progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first 2 days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the Combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than 6 weeks postpartum. If breastfeeding is between 6 weeks to 6 months postpartum, it is UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk postpartum. After day 21, additional contraception should be used for the first 7 days.

The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after 4 weeks. Meanwhile, the Lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than 6 months postpartum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

It should be noted that the woman already had hypertension before becoming pregnant. Blood pressure issues related to pregnancy, such as pre-eclampsia or pregnancy-induced hypertension, typically do not occur until after 20 weeks of gestation. The fact that her ambulatory blood pressure readings were elevated rules out the possibility of her hypertension being caused by anxiety in a medical setting. It is important to consider the possibility of secondary hypertension, as high blood pressure in a woman of this age is not typical.

Hypertension during pregnancy is a common condition that can be managed effectively with proper care. In normal pregnancy, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, if a pregnant woman develops hypertension, it is usually defined as a systolic blood pressure of over 140 mmHg or a diastolic blood pressure of over 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from booking readings can also indicate hypertension.

After confirming hypertension, the patient should be categorized into one of three groups: pre-existing hypertension, pregnancy-induced hypertension (PIH), or pre-eclampsia. PIH, also known as gestational hypertension, occurs in 3-5% of pregnancies and is more common in older women. If a pregnant woman takes an ACE inhibitor or angiotensin II receptor blocker for pre-existing hypertension, it should be stopped immediately, and alternative antihypertensives should be started while awaiting specialist review.

Pregnancy-induced hypertension in association with proteinuria, which occurs in around 5% of pregnancies, may also cause oedema. The 2010 NICE guidelines recommend oral labetalol as the first-line treatment for hypertension during pregnancy. Oral nifedipine and hydralazine may also be used, depending on the patient’s medical history. It is important to manage hypertension during pregnancy effectively to reduce the risk of complications and ensure the health of both the mother and the baby.

Treatment of C. trachomatis Infection in Pregnancy

C. trachomatis infection is becoming more common in the UK and can lead to adverse fetal outcomes such as spontaneous miscarriage, premature rupture of membranes, and intrauterine growth retardation. Therefore, treatment is advised ahead of test results if chlamydia is strongly suspected clinically. Current UK guidelines recommend three different options for pregnant patients: erythromycin, amoxicillin, and azithromycin. However, erythromycin is the most appropriate option as it is the recommended treatment by most guidelines. Doxycycline, co-trimoxazole, and metronidazole are not routinely used in the treatment of chlamydia during pregnancy. It is also important to note that pregnant patients should be tested for cure 5 weeks after completing treatment (or 6 weeks if azithromycin is used).

Understanding Parity and Its Relationship with Gravity

Parity refers to the number of pregnancies a woman has had that have been carried to a viable age, which is typically 24 weeks in the UK. This number is represented by a digit followed by a plus sign and another digit, which indicates the number of pregnancies that did not reach viability. Essentially, parity reflects the number of babies a woman has given birth to, while gravida refers to the number of times a woman’s uterus has contained a fetus, regardless of whether the pregnancy resulted in a live birth.

It’s worth noting that parity only increases once a baby is born, whereas gravida increases from conception. For instance, if a woman has given birth to twins, her parity would be 2, while her gravida would be 1. Understanding the difference between parity and gravida is important for healthcare providers to accurately assess a woman’s obstetric history and provide appropriate care.

Managing Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. Its management is complex due to the unclear cause of the condition. However, it is known that PCOS is associated with high levels of luteinizing hormone and hyperinsulinemia, and there is some overlap with the metabolic syndrome. General management includes weight reduction if appropriate and the use of combined oral contraceptives (COC) to regulate the menstrual cycle and induce a monthly bleed.

Hirsutism and acne are common symptoms of PCOS, and a COC pill may be used to manage them. Third-generation COCs with fewer androgenic effects or co-cyprindiol with an anti-androgen action are possible options. If these do not work, topical eflornithine may be tried, or spironolactone, flutamide, and finasteride may be used under specialist supervision.

Infertility is another issue that women with PCOS may face. Weight reduction is recommended if appropriate, and the management of infertility should be supervised by a specialist. There is an ongoing debate about whether metformin, clomifene, or a combination should be used to stimulate ovulation. A 2007 trial published in the New England Journal of Medicine suggested that clomifene was the most effective treatment. However, there is a potential risk of multiple pregnancies with anti-oestrogen therapies such as clomifene. The RCOG published an opinion paper in 2008 and concluded that on current evidence, metformin is not a first-line treatment of choice in the management of PCOS. Metformin is also used, either combined with clomifene or alone, particularly in patients who are obese. Gonadotrophins may also be used.

It is important to screen pregnant women for bacteriuria as untreated cases may lead to acute pyelonephritis. Therefore, taking no action based on urine results is inappropriate. Trimethoprim is not recommended in the first trimester due to its teratogenic risk, so nitrofurantoin is a better option. Local prescribing guidelines should always be followed. If group B streptococcal bacteriuria is detected, antenatal services must be informed as prophylactic intrapartum antibiotics will be necessary.

Urinary tract infections (UTIs) are common in adults and can affect different parts of the urinary tract. Lower UTIs are more common and can be managed with antibiotics. For non-pregnant women, local antibiotic guidelines should be followed, and a urine culture should be sent if they are aged over 65 years or have visible or non-visible haematuria. Trimethoprim or nitrofurantoin for three days are recommended by NICE Clinical Knowledge Summaries. Pregnant women with symptoms should have a urine culture sent, and first-line treatment is nitrofurantoin, while amoxicillin or cefalexin can be used as second-line treatment. Asymptomatic bacteriuria in pregnant women should also be treated with antibiotics. Men with UTIs should be offered antibiotics for seven days, and a urine culture should be sent before starting treatment. Catheterised patients should not be treated for asymptomatic bacteria, but if they are symptomatic, a seven-day course of antibiotics should be given, and the catheter should be removed or changed if it has been in place for more than seven days. For patients with signs of acute pyelonephritis, hospital admission should be considered, and local antibiotic guidelines should be followed. The BNF recommends a broad-spectrum cephalosporin or a quinolone for 10-14 days for non-pregnant women.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than one per 100 woman years. It is a convenient option that doesn’t interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to consider. One of the main drawbacks is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections, so additional precautions may be necessary. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side effects such as headache, nausea, and breast tenderness may also be experienced.

Despite some reports of weight gain, a Cochrane review did not find a causal relationship between the combined oral contraceptive pill and weight gain. Overall, the combined oral contraceptive pill can be a safe and effective option for birth control, but it is important to weigh the pros and cons and discuss any concerns with a healthcare provider.

When using Ellaone, it is recommended to wait for 5 days before starting the combined contraceptive pill and to use barrier contraception for 7 days. This is because taking progestogen within 5 days of using Ulipristal may reduce its effectiveness as an emergency contraceptive. Waiting for this period and avoiding further unprotected sexual intercourse ensures that Ellaone is as effective as possible in preventing pregnancy. When starting the combined contraceptive pill, patch, or ring, or the progesterone-only implant or injection, barrier contraception should be used for 7 days. For Qlaira contraceptive pill, barrier contraceptives should be used for 9 days, and for the progesterone-only pill, for 2 days after starting the method.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

Premature Menopause: Causes and Ethnic Differences

Studies have not found a correlation between the age at which a woman experiences menarche and the age at which she enters menopause. However, premature menopause may be linked to various factors such as smoking, living at high altitudes, and poor nutritional status. Additionally, there may be a genetic predisposition to early menopause. While there is no evidence of ethnic differences in the age of menopause, certain ethnic groups may be more susceptible to specific causes of premature menopause.